Population pharmacokinetics of efalizumab (humanized monoclonal anti-CD11a antibody) following long-term subcutaneous weekly dosing in psoriasis subjects

Item request has been placed! ×
Item request cannot be made. ×
  Processing Request
  • Additional Information
    • Publication Information:
      Sage Publications, Inc.
    • Publication Date:
      2005
    • Abstract:
      The population pharmacokinetics of efalizumab was characterized in patients with moderate to severe plaque psoriasis. The study included 1088 subjects who received 1 or 2mg/kg/ wk subcutaneous efalizumab for 12 [...]
    • ISSN:
      0091-2700
    • Rights:
      Copyright 2005 Gale, Cengage Learning. All rights reserved.
      COPYRIGHT 2005 Sage Publications, Inc.
    • Accession Number:
      edsgcl.140794869
  • Citations
    • ABNT:
      SUN, Y.-N. et al. Population pharmacokinetics of efalizumab (humanized monoclonal anti-CD11a antibody) following long-term subcutaneous weekly dosing in psoriasis subjects. Journal of Clinical Pharmacology, [s. l.], n. 4, p. 468, 2005. Disponível em: . Acesso em: 21 ago. 2019.
    • AMA:
      Sun Y-N, Lu J-F, Joshi A, Compton P, Kwon P, Bruno RA. Population pharmacokinetics of efalizumab (humanized monoclonal anti-CD11a antibody) following long-term subcutaneous weekly dosing in psoriasis subjects. Journal of Clinical Pharmacology. 2005;(4):468. http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edsghw&AN=edsgcl.140794869. Accessed August 21, 2019.
    • APA:
      Sun, Y.-N., Lu, J.-F., Joshi, A., Compton, P., Kwon, P., & Bruno, R. A. (2005). Population pharmacokinetics of efalizumab (humanized monoclonal anti-CD11a antibody) following long-term subcutaneous weekly dosing in psoriasis subjects. Journal of Clinical Pharmacology, (4), 468. Retrieved from http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edsghw&AN=edsgcl.140794869
    • Chicago/Turabian: Author-Date:
      Sun, Yu-Nien, Jian-Feng Lu, Amita Joshi, Peter Compton, Paul Kwon, and Rene A. Bruno. 2005. “Population Pharmacokinetics of Efalizumab (Humanized Monoclonal Anti-CD11a Antibody) Following Long-Term Subcutaneous Weekly Dosing in Psoriasis Subjects.” Journal of Clinical Pharmacology, no. 4: 468. http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edsghw&AN=edsgcl.140794869.
    • Harvard:
      Sun, Y.-N. et al. (2005) ‘Population pharmacokinetics of efalizumab (humanized monoclonal anti-CD11a antibody) following long-term subcutaneous weekly dosing in psoriasis subjects’, Journal of Clinical Pharmacology, (4), p. 468. Available at: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edsghw&AN=edsgcl.140794869 (Accessed: 21 August 2019).
    • Harvard: Australian:
      Sun, Y-N, Lu, J-F, Joshi, A, Compton, P, Kwon, P & Bruno, RA 2005, ‘Population pharmacokinetics of efalizumab (humanized monoclonal anti-CD11a antibody) following long-term subcutaneous weekly dosing in psoriasis subjects’, Journal of Clinical Pharmacology, no. 4, p. 468, viewed 21 August 2019, .
    • MLA:
      Sun, Yu-Nien, et al. “Population Pharmacokinetics of Efalizumab (Humanized Monoclonal Anti-CD11a Antibody) Following Long-Term Subcutaneous Weekly Dosing in Psoriasis Subjects.” Journal of Clinical Pharmacology, no. 4, 2005, p. 468. EBSCOhost, search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edsghw&AN=edsgcl.140794869.
    • Chicago/Turabian: Humanities:
      Sun, Yu-Nien, Jian-Feng Lu, Amita Joshi, Peter Compton, Paul Kwon, and Rene A. Bruno. “Population Pharmacokinetics of Efalizumab (Humanized Monoclonal Anti-CD11a Antibody) Following Long-Term Subcutaneous Weekly Dosing in Psoriasis Subjects.” Journal of Clinical Pharmacology, no. 4 (2005): 468. http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edsghw&AN=edsgcl.140794869.
    • Vancouver/ICMJE:
      Sun Y-N, Lu J-F, Joshi A, Compton P, Kwon P, Bruno RA. Population pharmacokinetics of efalizumab (humanized monoclonal anti-CD11a antibody) following long-term subcutaneous weekly dosing in psoriasis subjects. Journal of Clinical Pharmacology [Internet]. 2005 [cited 2019 Aug 21];(4):468. Available from: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edsghw&AN=edsgcl.140794869